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Biopharmaceuticals can be described as medicines or medicinal products manufactured through 
biotechnological processes with links to biological sources especially those of live organisms or their 
active components. The biopharmaceutical industry is presently experiencing tremendous revenue 
growth rates projected at more than $167 billion worldwide in 2015. There are more than 500 
biopharmaceutical products that have been approved with about 400 presently marketable in the United 
States and European markets. The full potential of biopharmaceutical, biotechnology, genomic, genetic 
and biogeneric compounds is best realized in small entrepreneurial firms which have the capacity for 
creativity, risk, flexibility and iteration that no large biopharmaceutical entity can match. Although there 
are challenges facing African Small and Medium Enterprises (SMEs) in biopharmaceutical industry, the 
prospects on the other hand can be lucrative taking into cognizance Africa’s ever increasing population 
and the need for affordable health care. To facilitate the contribution of SMEs in Africa, this article 
presents a perspective on the prospects of African SMEs in biopharmaceutical innovations such as new 
products, processes and services. The roles of SMEs in the global biopharmaceutical industry are 
reviewed. Additionally, selected critical factors to accelerate the contribution of African SMEs in global 
biopharmaceutical innovation are described. Finally, the prospective areas for biopharmaceutical 
innovation in Africa include research and development, marketing, workforce development and contract 
manufacturing. 
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INTRODUCTION 
 
Biopharmaceuticals can be described as 
medicine or medicinal products with links to 
biological sources especially those of live 
organisms or their active components that 
has been manufactured through 
biotechnological processes [1]. The 
biopharmaceutical industry’s foundation can 
be traced back to research by Stanley Cohen 
and Herbert Boyer on recombinant 
deoxyribonucleic acid (DNA), which has now 
grown into a multi-billion dollars industry that 
currently spends $21 billion on research and 
development (R&D) annually and has 
successfully commercialized over 400 
products [2].  
 
Presently the biopharmaceutical industry is 
experiencing tremendous growth as the 
industry witnessed between 15%-17% 
revenue growth rates in 2004, amounting to 
$45 billion, which is twice the growth rate of 
the global pharmaceutical market [3]. 
Therefore, it is projected that revenues will hit 
a mark of $90 billion in 2011. Global 
revenues are projected to increase by more 
than $167 billion by 2015 [4]. Further, the 
biopharmaceutical market in the United 
States (U.S.) accounted for about 60% of the 
global pharmaceutical market in 2004, 
followed by Europe with about 20% and lastly 
Asia and the Middle East with Africa 
significantly absent [4]. BioPlan Associates in 
2005 (reported by [5]) conducted a research 
on capacity constraints in the 
biopharmacetical sector and found that 
amongst the respondents, 34% were 
currently faced with serious capacity 
constraints and more than 42% will 
experience constraints in about five years. 
Nevertheless, the growth rate of global 
biopharmaceuticals manufacturing is 
expected to exceed demand; with around 
1.37 million litres in 2004 to 3.13 million litres 
increase in 2011 [5].  
 
Various estimates exist in connection with 
pharmaceuticals R&D investments, and time 
required to market a product. The cost of 
pharmaceutical product development in the 
U.S. increased from $54 million in 1979 to 
$800 million in 2001 [6]. Factors that 
contribute to the cost include the place where 
development and clinical trials are carried out 
as well as issues associated with meeting 
regulatory approval. The time from beginning 
of R&D to marketable product is estimated as 
7 to 18 years [7].  
 
Small and Medium Enterprises (SMEs) are 
independent firms with the number of 
employees varying from one region to 
another. The growth of biopharmaceutical 
innovations (for example, introduction of new 
products, processes and services) in the 
United States and Europe has been 
attributed to SMEs. Though raw materials 
(such as medicinal plants) for 
biopharmaceutical R&D abound in Africa, the 
contribution of Africa countries to 
biopharmaceutical innovation has not been 
significant. The possible reasons for this 
situation include inadequate funding for 
various aspects of the biopharmaceutical 
development.  
 
There are current national and continent wide 
initiatives to catalyze biopharmaceutical 
research and development in Africa. For 
example, in Nigeria, the National 
Biotechnology Development Agency 
(NABDA) through World Bank assistance is 
catalyzing the infusion of biotechnologies for 
biopharmaceutical product development into 
the country’s pharmacy training curriculum 
[8]. Further, the African Network for Drug and 
Diagnostics (ANDI) established in 2008 has 
the goal to promote and sustain African-led 
product R&D innovation through the 
discovery, development and delivery of 
affordable new tools, including those based 
on traditional medicines [9]. The African 
Network for Drug and Diagnostics recognizes 
the importance of African entrepreneurship 
especially to sustainably address the burden 
of neglected tropical diseases of poverty [10]. 
 
To facilitate the contribution of SMEs in 
Africa, this article presents a perspective on 
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the prospects of African SMEs in 
biopharmaceutical innovation. The roles of 
SMEs in the global biopharmaceutical 
industry and then provides a model for the 
contribution of African SMEs in global 
biopharmaceutical innovation.  
 
Small and Medium Enterprises 
(SMEs) in biopharmaceuticals 
 
The European Union (EU) defines SME as 
the number of employees of around 250 
whereas in the United States (U.S.) it is set at 
less than 500. Some other countries consider 
SMEs as those firms with not more than 200 
employees while others have no fixed limit 
[11]. However, in line with the EUs definition, 
enterprises with less than 250 employees 
should have turnover of less than €50 million 
and yearly balance sheet of less than €43 
million [11]. 
 
The full potential of biopharmaceutical, 
biotechnology, genomic, genetic and 
biogeneric compounds is best realized in 
small entrepreneurial firms, which have 
capacity for creativity, flexibility, risk and 
iteration that no large biopharmaceutical 
entity can match [12, 13]. SMEs have proven 
to convert federal funding into patents, 
licenses and products introductions more 
than larger companies [14]. 
 
There are indications that SMEs have not 
played significant role towards innovation in 
the pharmaceutical industry in the past [15]. It 
has been argued that SMEs have contributed 
towards innovation process where the 
conventional ”academia-industry” research 
model has transformed to form a triangular 
model. However, this has been contradicted 
by some other research [16, 17]. Alliances 
between small biotechnology and big 
pharmaceutical firms in the U.S. show that 
the later are more drawn to alliances solely 
for commercial exploitation rather than for 
exploration purposes. This obviously leaves 
the small biotech firms to wind up in the 
cause of time [18]. A detailed review of the 
trend in U.S. biotech/pharma sector 
concluded that cumulatively SMEs have 
created impressive revenue growth with 
profitability still at a low level in comparison to 
the pharmaceutical industry in general [19] . 
 
Over the years, research have shown that 
biopharmaceuticals industry is a lucrative 
business area and also growing at a fast 
pace [19]. The global biopharmaceutical 
market experienced growth of between 15-
17% increase in 2004, which is even twice 
more than the global pharmaceutical market 
[3]. It accounted for $45 billion in revenues in 
that same year which is estimated to be 
about 8.1% of the total global pharmaceutical 
market. Projections show that revenues might 
reach $92 billion in 2011 at an average 
annual growth rate of 10.3% between the 
2004 and 2011. Further, research have 
shown a move from the traditional trial-and-
error drug discovery approaches to a more 
science based deductive approaches, 
through the search for new target, but with 
great emphasis on forming ties between 
biotechnological and biopharmaceuticals 
companies [20, 21].   
 
There is no doubt that biopharmaceuticals 
continues to be an important and developing 
aspect of the pharmaceutical market with its 
increasing profit margin.  There are more 
than 500 biopharmaceutical products that 
have been approved with about 400 presently 
marketable both in the U.S. and European 
markets. Of this number, 159 are 
recombinant protein and monoclonal antibody 
products. As of September 2010, the FDA 
had granted 14 full approvals to new 
biopharmaceutical products (Table 1). It was 
estimated that up to 20 approvals will be 
granted before the end of 2010 which will be 
the largest number approved by FDA since 
1998 [22]. 
 
The current trend is that most of the 
biopharmaceutical firms invest close to 15% 
of their sales revenue on R&D and in some 
cases the total annual cost sum up to  
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Table 1: Biopharmaceutical products approved by FDA in 2010 
 
Product Company Indication(s) 
Xeomin (Botulinum Toxin A)  Merz Pharmaceuticals  Cervical dystonia or 
blepharospasm  
Glassia (alpha-1 antitrypsin)  Kamada Ltd.  Alpha1-antitrypsin deficiency  
Prolia (RANKL Mab, rDNA)  Amgen Osteoporosis  
Lumizyme (glucosidase alpha)  Genzyme  Pompe disease  
Provenge (cellular vaccine)  Dendreon Corp.  Prostate cancer  
Pancreaze (pancreatic enzymes)  Johnson & Johnson  Pancreatic insufficiency  
TachoSil (Fibrin Sealant Patch)  Nycomed Austria GmbH  Control bleeding  
Vivaglobin (Immune Globulin  
Subcutaneous)  
CSL Behring  Primary immunodeficiency  
Glucocerebrosidase, rDNA  
(velaglucerase)  
Shire Pharmaceutical  
 
Gaucher disease  
 
Prevnar 13 (13-antigen 
pneumococcal vaccine)  
Pfizer/Wyeth  
 
Pneumonia prevention  
 
Menveo (Meningococcal vaccine)  Novartis  Meningococcal disease prevention  
Collagenase (enzyme)  Auxilium Pharmaceuticals  Dupuytren's disease  
Victoza (Glucagon-like peptide-1,  Novo  Type 2 diabetes  
Actemra (Interleukin-6 receptor 
Mab,  rDNA)  
Amgen  
 
Rheumatoid arthritis (RA)  
 
  Source: Langer, [22] p4 
 
billions of dollars. The globalization of 
markets, regionalization of technical and 
scientific knowledge and complexity of drug 
discovery process are reasons advanced for 
this investment decision. For the past 20 
years, there has been a shift from the basic 
research operations from the trial-and-error 
drug discovery process to science focused 
deductive approach.  This has led to a close 
connection between biotechnology and 
biopharmaceutical firms to carry out 
biopharmaceuticals research [20, 21, 23]. 
 
The big traditional pharmaceutical firms are 
taking advantage of biotechnology through 
the forming of alliance with biotechnology 
firms at different stages of the drug 
development life cycle. Also, there is an 
increasing number of big pharmaceutical 
companies that are forming strategic 
alliances with innovation-rich biotechnology 
firms, or outright purchase of the firms. 
Among the Top 10 biopharmaceutical 
companies in 2004 were Amgen, Genentech, 
Serono, Biogen Idec, Genzyme (Table 2) [3]. 
In 2006, Big Pharmaceuticals companies 
spent roughly $17 billion for more than 250 
biotech deals, up from 150 in 2003 [24]. 
 
PROSPECTS FOR AFRICAN SMES 
IN BIOPHARMACEUTICALS 
 
The development of SMEs in Africa is seen 
as boosting up the realization of wider 
economic and socio-economic activities 
thereby alleviating of poverty through the 
provision of employment, generating of extra 
source of capital for large-scale production. 
However, a report by the International 
Finance Corporation (IFC) indicates that 
there are between 30 to 37 million SMEs in 
Africa that are not adequately financed; this 
has consequently created a value gap in 
credit financing of around $140 and $170 
billion. SMEs plays a key role in Africa 
economies with a contribution of about 75% 
in terms of employment within the continent 
[25].  
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Table 2: Top Biopharmaceutical companies profit in 2004 
 
Companies Total Profit (Billion) $ Top Products Growth rate % 
Amgen 9.97 Epogen, Aranesp, Enbrel, 
Neulasta and Neupogen 
27 




Serono 2.17 Rebif 17 
Biogen Idec 2.11 Avonex 23 
  Source of Data: Parmar [3].  
 
Factors such as privatization, specialization, 
corporate restructuring and downsizing are 
encouraging the growth of SMEs within Africa 
[26-28].  However, there are many major 
challenges being faced by entrepreneurs in 
Africa. These include financial resources, 
tools and the required skilled labor [29-31]. 
The trend however is changing as African 
countries are now embracing possible ways 
to tackle the issue of finance through the 
introduction of credit facilities to SMEs either 
as startups or for expansion purposes. 
Government of many developing countries in 
Africa are formulating policies and measures 
to support SMEs given that they now 
recognize its contribution towards the growth 
of economy [32].  
 
A workshop organized in 2000 by the 
Economic Commission for Africa (ECA) found 
that SMEs within Africa function under 
unstable, unregulated, unintegrated and 
uncompetitive environments which has 
adverse effect on the education and training 
policies, and R&D facilities and deficient 
capacities [33]. There is the notion that 
unless adequate environment for productive 
functionality is in place, integration into the 
global scene would almost be impossible. 
Though the workshop was help over 10 years 
ago recommendations to African 
governments may be still be relevant. These 
recommendations include: (1) introduce 
policies and regulator structure with the 
intention of developing the industries’ 
competitiveness locally and internationally; 
(2) get involved in programs that promotes 
suitable environment for business; (3) 
formulate mechanism to bring together close 
association between private and public 
sector; and (4) introduce strategies and 
programs for national economic development 
through access to income-earning 
opportunities, training and development of 
human resources, formulation of enterprise 
development programmes and financing 
schemes targeted at women entrepreneurs, 
access to improved quality of working 
conditions, as well as access to domestic and 
international markets and promotion of good 
relations between employers and workers 
thereby increasing the productivity of 
enterprises and organisations through a 
shared vision [33]. 
 
The success of African SMEs in 
biopharmaceuticals would depend on some 
critical factors such as innovation, R & D, 
marketing, contract manufacturing and work 
force development. Prospects for African 
SMEs in the biopharmaceutical industry in 
terms of innovation lie in the strength of 
alliance, a current trend in the biopharma-
ceuticals industry. With efforts from 
developing countries to promote innovation, 
there are prospects that African SMEs 
benefiting from such ventures that will lead to 
economic growth. African SMEs will benefit 
from the international biopharma-ceutical 
industry through the sharing of knowledge in 
the development and marketing of new 
products or processes. Through alliance, 
African SMEs will be able to access newly 
emerging technologies for biomanufacturing. 
Further, inter-African SMEs partnerships can 
accelerate innovation and competitiveness of 
Awaritoma et al   
Trop J Pharm Res, August 2011;10 (4): 528 
African SMEs in the global biopharmaceutical 
industry.  
 
Marketing is a crucial component in the 
biopharmaceutical industry. The effective 
introduction of biopharmaceutical products 
into the African market or African 
biopharmaceutical products to the 
international market can be hindered by 
limited capital. Alliances for marketing of 
biopharmaceutical products from African 
SMEs can help boost sales and provide an 
efficient avenue for biopharmaceutical 
product sale in the Africa.  
 
Biomanufacturing is both capital and labor-
intensive and requires specialized and 
experienced workforce. Often, many firms in 
Africa may face the problems of adequate 
funding and poor quality of the workforce. 
African SMEs in biopharmaceuticals can gain 
advantage through the contracting of the 
manufacturing of its herbal medicines to 
international biomanufacturing companies. 
The possibility that African SMEs can utilize 
the expertise of contract manufacturing 
companies will enable African SMEs to focus 
on core areas. This strategy has the potential 
of lowering production costs and improving 
manufacturing efficiency.  
 
With the advent of new manufacturing 
technologies, there is increase need to 
develop the workforce in advanced 
technologies. Developing countries will 
benefit from international biopharmaceutical 
companies in the area of training the needed 
workforce to cope with the technological 
change in the industry.  
   
CONCLUSION 
 
The biopharmaceutical industry is 
experiencing tremendous growth in terms of 
revenue and new biopharmaceutical products 
with small and medium enterprises 
contributing to its growth. The contribution of 
Africa SMEs has not been significant due to 
financial constraints and deficient quality 
workforce. However, new governmental 
initiatives for SME financing as well as 
research and development in academic 
institutions provide inputs for catalyzing 
significant contributions of African SMEs in 
the global biopharmaceutical industry. Finally, 
the prospective areas for biopharmaceutical 
innovation in Africa include research and 
development, marketing, workforce develop-
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